Novo Nordisk is acquiring Cardior Pharmaceuticals for up to $1.1 billion to add new drug candidates to its cardiometabolic pipeline. Cardior focuses on RNA targeting for heart disease and its lead candidate, CDR132L, is in Phase 2 development for heart failure. The deal, slated to close in the second quarter, does not disclose the upfront payment or milestone details. Both companies are expected to benefit from this acquisition, allowing Novo Nordisk to bolster its portfolio of cardiometabolic medicines.
Source link
Novo Nordisk to buy Cardior, building up pipeline of heart drugs
